Emergent BioSolutions price target raised to $8 from $5 at Benchmark

Benchmark raised the firm’s price target on Emergent BioSolutions to $8 from $5 and keeps a Buy rating on the shares. Shares have continued their upward momentum this spring following a positive Q1 earnings report, recent progress by licensee Bavarian Nordic on its chikungunya vaccine candidate, growing public awareness for anti-opioid solutions including Emergent’s NARCAN nasal spray, as well as increased public awareness of the need for preparedness from biological threats such as the recent Avian Flu outbreak, the analyst tells investors in a research note.